RecruitingPhase 1Phase 2NCT06591793

Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa

Sponsor

AAVantgarde Bio Srl

Enrollment

15 participants

Start Date

Jul 2, 2024

Study Type

INTERVENTIONAL

Conditions

Usher Syndrome, Type 1B

Summary

The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AAVB-081 for people with usher syndrome, type 1b. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAAVB-081

Single subretinal administration

Locations(3)

University of Campania Luigi Vanvitelli

Naples, Italy

Moorfields Eye Hospital

London, United Kingdom

Retina Clinic London

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06591793